DC
IOVA icon

Diametric Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Diametric Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,327
Closed -$40.1K – 439
2025
Q2 		$40.1K Buy
+23,327
New +$58K 0.02% 307
2020
Q3 		– Sell
-17,156
Closed -$471K – 151
2020
Q2 		$471K Buy
17,156
+3,971
+30% +$131K 0.36% 78
2020
Q1 		$395K Buy
+13,185
New +$349K 0.48% 65

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Diametric Capital's IOVA Position: Q3 2025 in Review

Diametric Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 23,327 shares — an estimated $40.1K sold.

Diametric Capital first reported a position in IOVA in Q1 2020 and held it in 3 quarters. The position peaked at $471K in Q2 2020. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Diametric Capital reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Diametric Capital sold 23,327 Iovance Biotherapeutics shares in Q3 2025, an estimated $40.1K.
  • Diametric Capital first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 3 quarters.
  • Diametric Capital's Iovance Biotherapeutics position peaked at $471K in Q2 2020.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Diametric Capital's 13F filing for Q3 2025, filed 13 Nov 2025.